Learn More
BACKGROUND We previously identified a functional variant in a let-7 microRNA (miRNA) complementary site in the 3'-untranslated region of the KRAS oncogene (rs61764370) which is associated with cancer. We aimed to investigate the association of this KRAS variant with breast cancer and tumour biology. METHODS We assessed frequency distributions of the KRAS(More)
Germline variants in the 3' untranslated region (3'UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3'UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act(More)
The aim of this study was to determine whether giving influenza vaccine to pregnant women can reduce the incidence of hospitalization due to influenza in their infants in the first year of life. This was a matched, hospital-based case-control study at Yale-New Haven Children's Hospital. Case and control subjects were all aged <12 months at the time of their(More)
OBJECTIVE The purpose was to describe (a) individuals' reasons for participating in cognitive screening and (b) reasons to pursue testing after screening across 4 ethnic groups: African American, Afro-Caribbean, European American, and Hispanic American. METHODS Prior to memory screening, 119 adults were interviewed regarding their thoughts about memory(More)
Ovarian cancer (OC) is the fifth leading cause of cancer death in women. High mortality rates are due to vague symptoms of early disease, leading to diagnosis at a late stage. Approximately 10% of OCs are considered hereditary. The KRAS-variant is an inherited, germline variant that has been demonstrated to serve as a genetic marker of increased risk of OC.(More)
  • 1